Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JM-010 for Levodopa-induced Dyskinesia in PD
NCT02439203Phase 2Completed
- Sponsor
- Bukwang Pharmaceutical
- Start
- May 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JM-010 in levodopa-induced dyskinesia (LID), sponsored by Bukwang Pharmaceutical. Started May 2015; status: completed.
02
Drugs
JM-010
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT02439203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02439203.